ADMA Biologics (ADMA) shares of the high growth biotech closed green Monday with a strong bull candle reversal off the large volume support near 17 and could trigger a move back to highs if can clear 19 in a market that stabilizes from here. ADMA has held above its 200-day EMA during this whole market selloff and a break higher can see the former high near 23 once the markets recover. ADMA makes three FDA approved plasma-derived biologics for the treatment of immune deficiencies. ADMA has strong financials and guided 2025 revenues to $490+ million and 2026 revenues of $605M. May $19 calls bought last month at $2.60 still holding 2200x in OI while August $23 short calls also in OI so would make that 23 level a nice target perhaps.